

SECRETARY OF THE SENATE

APR 13 PM 4:07

H. D.

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name Pharmaceutical Research & Manufacturers of America			
2. Registrant Address <input type="checkbox"/> Check if different than previously reported Address 1100 15th Street, N.W., Suite 900 City Washington State/Zip (or Country) DC 20005 USA			
3. Principal Place of Business (if different from line 2) City _____ State/Zip (or Country) _____			
4. Contact Name Matthew B. Van Hook			5. Senate ID # 31350-12
7. Client Name <input checked="" type="checkbox"/> Self			6. House ID # 30654000

TYPE OF REPORT 8. Year 1999 Midyear (January 1-June 30) OR Year End (July 1-December 31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report >> Termination Date _____ 11. No Lobbying Activity

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13	
<p align="center">12. Lobbying Firms</p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more >> \$ _____ Income (nearest \$20,000)</p> <p>Provide a good faith estimate, rounded to the nearest \$20,000 of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p align="center">13. Organizations</p> <p>EXPENSES relating to lobbying activities for this reporting period were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input checked="" type="checkbox"/> >> \$ <u>\$2,200,000.00</u> Expenses (nearest \$20,000)</p> <p>14. REPORTING METHOD. Check box to indicate expense accounting method. See instructions for description of options.</p> <p><input checked="" type="checkbox"/> Method A. Reporting amounts using LDA definitions only</p> <p><input type="checkbox"/> Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code</p> <p><input type="checkbox"/> Method C. Reporting amounts under section 162(e) of the Internal Revenue Code</p>

Signature _____ Date 2/14/00

Printed Name and Title Matthew B. Van Hook - Deputy General Counsel Page 1 of 9

Registrant Name: Pharmaceutical Research & Manufacturers of America

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code CPT (one per page)
16. Specific Lobbying issues
H.R. 1225, U.S. Patent & Trademark Office Reauthorization Act, FY 2000,
H.R. 1598, Patent Fairness Act of 1999, (limited to support for the concept of patent term restoration).
H.R. 1907, American Inventors Protection Act of 1999,
S. 1172, Drug Patent Term Restoration Review Procedure Act of 1999, (limited to support for the concept of patent term restoration, except to also urge deletion of provisions different from H.R. 1598, which are unnecessary to the goals of H.R. 1598).
S. 1948, Intellectual Property and Communications Omnibus Act of 1999, (patent reform provisions)

17. House(s) of Congress and Federal agencies contacted Check if None
House of Representatives
Patent and Trademark Office
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Bello, Judith		No
Caldwell, Barry	Formerly Chief of Staff, Senator Arlen Specter	No
Currie, L. Rodger	Majority Counsel, House Commerce Committee	No
Holmer, Alan F.		No
Mohler, Dave T.		No
Van Hook, Matthew B.		No

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date 2/14/06

Printed Name and Title Matthew B. Van Hook - Deputy General Counsel Page 2 of 9

Registrant Name: Pharmaceutical Research & Manufacturers of America

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific Lobbying issues

- H.R. 10, Financial Services Modernization, provisions re confidentiality of health and medical information
- H.R. 1885, International Prescription Drug Parity Act,
- H.R. 2470, Medical Information Protection & Research Enhancement Act of 1999,
- H.R. 2782, The Seniors Prescription Insurance Coverage Equity Act of 1999,
- H.R. 664, Prescription Drug Fairness Act of 1999,
- S. 1191, International Prescription Drug Parity Act,
- S. 1480, The Seniors Prescription Insurance Coverage Equity Act of 1999,
- S. 578, Health Information Protection Act,
- S. 731, Prescription Drug Fairness Act of 1999,
- S. 881, Medical Information Protection Act of 1999,

17. House(s) of Congress and Federal agencies contacted Check if None
Department of Health & Human Services
Food & Drug Administration
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Bantham, Russel		No
Bello, Judith		No
Caldwell, Barry	Formerly Chief of Staff, Senator Arlen Specter	No
Cole, Steven		No
Currie, L. Rodger	Majority Counsel, House Commerce Committee	No
Guarducci, Mara	Legislative Assistant, Congressman Jim Greenwood	No
Holmer, Alan F.		No

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date 2/14/09

Printed Name and Title Matthew B. Van Hook - Deputy General Counsel Page 3 of 9

Registrant Name: Pharmaceutical Research & Manufacturers of America

Client Name: Self

Item	Description	Data
16	Lobbying Issues	Executive Branch: FDA implementation of P.L. 105-115, the FDA Modernization Act of 1997. OMB implementation of the provision in P.L. 105-277, the 1999 Appropriations Bill, regarding OMB Circular A-110 regarding public availability of research data produced under a federal grant.
18a	Lobbyist Name	Lucas, William
18b	Covered Official Position	
18c	New Lobbyist	No
18a	Lobbyist Name	Malmgren, Kurt
18b	Covered Official Position	
18c	New Lobbyist	No
18a	Lobbyist Name	Mohler, Dave T.
18b	Covered Official Position	
18c	New Lobbyist	No
18a	Lobbyist Name	Van Hook, Matthew B.
18b	Covered Official Position	
18c	New Lobbyist	No

Registrant Name: Pharmaceutical Research & Manufacturers of America

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific Lobbying issues

- H.R. 1495, Access Medicare Prescription Drug Coverage Act of 1999,
- H.R. 2012, Medicare Prescription Drug Act of 1999,
- H.R. 2375, Senior Prescription Drug Assistance Expansion Demonstration Act of 1999,
- H.R. 2925, Medicare Beneficiary Prescription Drug Assistance & Stop-Loss Protection Act of 1999,
- H.R. 2927, Affordable Prescription Drug Act,
- H.R. 664, Prescription Drug Fairness for Seniors Act of 1999,
- H.R. 886, Medicare Prescription Drug Coverage Act of 1999,
- S. 1204, Healthy Seniors Promotion Act of 1999,
- S. 1480, Seniors Prescription Insurance Coverage Equity Act of 1999,
- S. 1895, Medicare Preservation and Improvement Act of 1999,

17. House(s) of Congress and Federal agencies contacted Check if None
Health Care Financing Administration, Dept. of Health and Human Services
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
<u>Bejlo, Judith</u>		<u>No</u>
<u>Caldwell, Barry</u>	<u>Formerly Chief of Staff, Senator Arlen Specter</u>	<u>No</u>
<u>Cole, Steven</u>		<u>No</u>
<u>Currie, L. Rodger</u>	<u>Majority Counsel, House Commerce Committee</u>	<u>No</u>
<u>Guarducci, Mara</u>	<u>Legislative Assistant, Congressman Jim Greenwood</u>	<u>No</u>
<u>Halmer, Alan F.</u>		<u>No</u>
<u>Lucas, William</u>		<u>No</u>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date 2/14/00

Printed Name and Title Matthew B. Van Hook - Deputy General Counsel Page 5 of 9

Registrant Name: Pharmaceutical Research & Manufacturers of America

Client Name: Self

Item	Description	Data
16	Lobbying Issues	S. 841, Medicare Prescription Drug Coverage Act of 1999.
16	Lobbying Issues	Executive Branch: Medicare reimbursement issues.
18a	Lobbyist Name	Malmgren, Kurt
18b	Covered Official Position	
18c	New Lobbyist	No
18a	Lobbyist Name	Mohler, Dave T.
18b	Covered Official Position	
18c	New Lobbyist	No

Registrant Name: Pharmaceutical Research & Manufacturers of America

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

- 15. General issue area code TAX (one per page)
- 16. Specific Lobbying issues
H.R. 2488, Financial Freedom Act of 1999, re health care deductions
S. 1429, Taxpayer Refund Act of 1999,

- 17. House(s) of Congress and Federal agencies contacted Check if None
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Cole, Steven		No
Currie, L. Rodger		No
Guarducci, Mara	Legislative Assistant, Congressman Jim Greenwood	No
Holmer, Alan F.		No

- 19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date 2/14/00

Printed Name and Title Matthew B. Van Hook - Deputy General Counsel Page 7 of 9

Registrant Name: Pharmaceutical Research & Manufacturers of America

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code TRD (one per page)

16. Specific Lobbying issues
H.R. 434, Africa Growth & Opportunity Act,

17. House(s) of Congress and Federal agencies contacted Check if None

Department of Commerce
House of Representatives
Office of the United States Trade Representative
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
<u>Caldwell, Barry</u>	<u>Formerly Chief of Staff, Senator Arlen Specter</u>	<u>No</u>
<u>Herzfeld, Shannon S.S.</u>		<u>No</u>
<u>Lucas, William</u>		<u>No</u>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date 2/14/09

Printed Name and Title Matthew B. Van Hook - Deputy General Counsel Page 8 of 9

Registrant Name: Pharmaceutical Research & Manufacturers of America

Client Name: Self

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

21. Client new principal place of business (if different from line 20)

City _____ State/Zip (or Country) _____

22. New general description of client's business or activities

LOBBYIST UPDATE

23. Name of each previously reported individual who is **no longer** expected to act as a lobbyist for the client
Lichtenfels, Tara
Robillard, Lara

ISSUE UPDATE

24. General lobbying issues previously reported that **no longer** pertain

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Name	Address	Principal Place of Business (city and state or country)


26. Name of each previously reported organization that is **no longer** affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities

Name	Address	Principal Place of Business (city and state or country)	Amount of contribution for lobbying activities	Ownership % in client

28. Name of each previously reported foreign entity that **no longer** owns, or controls, or is affiliated with the registrant, client, or affiliated organization

Signature  Date 2/14/00

Printed Name and Title Matthew B. Van Hook - Deputy General Counsel Page 9 of 9